trending Market Intelligence /marketintelligence/en/news-insights/trending/zWTkQdBTOaQv1--cbd1eog2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Li Kang Biomedical swings to profit in Q2

Industry Top Trends 2021: Metals and Mining

TMT News & Research: 2020 Recap

The Evolution Of ESG Factors In Credit Risk Assessment: Corporate Governance


Charter, DIRECTV and Comcast rank as the top 'RSN-friendly' MVPDs

Li Kang Biomedical swings to profit in Q2

Li Kang Biomedical Co. Ltd. said its normalized net income for the second quarter amounted to 57 Taiwan cents per share, compared with a loss of 27 cents per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$12.6 million, compared with a loss of NT$2.2 million in the prior-year period.

The normalized profit margin rose to 8.8% from negative 4.5% in the year-earlier period.

Total revenue increased on an annual basis to NT$142.9 million from NT$48.8 million, and total operating expenses climbed on an annual basis to NT$123.0 million from NT$52.2 million.

Reported net income totaled NT$20.1 million, or 91 cents per share, compared to a loss of NT$2.8 million, or a loss of 34 cents per share, in the prior-year period.

As of Aug. 11, US$1 was equivalent to NT$32.22.